Mainz, Germany

Matthias Birtel

This inventor holds 2 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Biontech Cell & Gene Therapies Gmbh, Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh. Active years: 2023-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthias Birtel. Retrieved from https://idiyas.com/inventor/matthias-birtel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 4.4

ph-index = 1


Company Filing History:


Years Active: 2023-2026

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Matthias Birtel: Innovator in Antigen Receptor Technology

Introduction

Matthias Birtel is a notable inventor based in Mainz, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of antigen receptors for therapeutic applications. His work focuses on innovative treatments for diseases by targeting specific cells that express antigens on their surface.

Latest Patents

Matthias Birtel holds a patent titled "Antigen receptors and uses thereof." This invention encompasses the treatment of diseases by targeting cells that express specific antigens. The technology involves recombinant antigen receptors, which can be utilized in T cells engineered to express these receptors. This advancement is particularly useful in treating diseases characterized by the expression of one or more antigens bound by the antigen receptors.

Career Highlights

Throughout his career, Matthias Birtel has worked with prominent organizations in the field of biotechnology. He has been associated with Tron—Translationale Onkologie an Der Universitätsmedizin Der Johannes Gutenberg—Universität Mainz Gemeinnützige GmbH and BioNTech Cell & Gene Therapies GmbH. His work in these companies has contributed to the advancement of cancer therapies and gene treatments.

Collaborations

Matthias has collaborated with esteemed colleagues, including Ralf Holger Voss and Ugur Sahin. These partnerships have fostered innovation and development in the field of antigen receptor technology.

Conclusion

Matthias Birtel's contributions to the field of biotechnology, particularly through his patent on antigen receptors, highlight his role as an innovator in medical treatments. His collaborations and career achievements reflect his commitment to advancing healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…